JP2022511673A - 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用 - Google Patents

運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用 Download PDF

Info

Publication number
JP2022511673A
JP2022511673A JP2021523904A JP2021523904A JP2022511673A JP 2022511673 A JP2022511673 A JP 2022511673A JP 2021523904 A JP2021523904 A JP 2021523904A JP 2021523904 A JP2021523904 A JP 2021523904A JP 2022511673 A JP2022511673 A JP 2022511673A
Authority
JP
Japan
Prior art keywords
dystonia
patient
disease
pharmaceutically acceptable
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021523904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511673A5 (https=
Inventor
マシュー・デューリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2022511673A publication Critical patent/JP2022511673A/ja
Publication of JP2022511673A5 publication Critical patent/JP2022511673A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021523904A 2018-11-05 2019-11-05 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用 Withdrawn JP2022511673A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755674P 2018-11-05 2018-11-05
US62/755,674 2018-11-05
PCT/US2019/059822 WO2020097045A1 (en) 2018-11-05 2019-11-05 Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders

Publications (2)

Publication Number Publication Date
JP2022511673A true JP2022511673A (ja) 2022-02-01
JP2022511673A5 JP2022511673A5 (https=) 2022-11-14

Family

ID=70460237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523904A Withdrawn JP2022511673A (ja) 2018-11-05 2019-11-05 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用

Country Status (10)

Country Link
US (2) US20200138785A1 (https=)
EP (1) EP3860595A4 (https=)
JP (1) JP2022511673A (https=)
KR (1) KR20210087952A (https=)
CN (1) CN113260362A (https=)
AU (1) AU2019377074A1 (https=)
CA (1) CA3118688A1 (https=)
IL (1) IL282189A (https=)
MX (1) MX2021005291A (https=)
WO (1) WO2020097045A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026501665A (ja) * 2023-01-19 2026-01-16 湖南明瑞制薬股▲ふん▼有限公司 神経ステロイド誘導体及びその用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077470A (zh) * 2023-02-06 2023-05-09 青岛润昕德生物医药有限公司 一种加奈索酮制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032553A1 (en) * 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
US7858609B2 (en) * 2005-11-28 2010-12-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
US9629853B2 (en) * 2014-05-21 2017-04-25 Wisconsin Alumni Research Foundation Uses of ganaxolone
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CA2973140C (en) * 2015-02-06 2025-09-16 Marinus Pharmaceuticals, Inc. Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
DK3364993T3 (da) * 2015-10-22 2023-01-09 Cavion Inc Fremgangsmåder til behandling af angelman syndrom
KR20240157128A (ko) * 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
EP3481387A4 (en) * 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026501665A (ja) * 2023-01-19 2026-01-16 湖南明瑞制薬股▲ふん▼有限公司 神経ステロイド誘導体及びその用途

Also Published As

Publication number Publication date
US20200138785A1 (en) 2020-05-07
CN113260362A (zh) 2021-08-13
IL282189A (en) 2021-05-31
EP3860595A1 (en) 2021-08-11
EP3860595A4 (en) 2021-11-10
CA3118688A1 (en) 2020-05-14
MX2021005291A (es) 2021-06-18
AU2019377074A1 (en) 2021-05-13
KR20210087952A (ko) 2021-07-13
US20220110917A1 (en) 2022-04-14
WO2020097045A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
JP2022058688A (ja) てんかん性障害の処置のための方法および組成物
TWI763632B (zh) 用於重症治療時之鎮靜方法及非口服調配物
CA3077514C (en) Delayed release deferiprone tablets and methods of using the same
KR20200018485A (ko) 우울 장애들의 치료
KR101298348B1 (ko) 조루증 치료를 위한 경구용 의약 조성물
JP2022511673A (ja) 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用
WO2020039263A2 (en) Pharmaceutical suspension for oral dosage
WO2024020598A1 (en) Methods of administering nalbuphine
US20230285369A1 (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US20220040120A1 (en) Pharmaceutical formulations containing gaboxadol for therapeutic treatment
US11364228B2 (en) Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
HK40121582A (zh) 用於治疗癫痫性紊乱的方法和组合物
US20230028539A1 (en) Pharmaceutical composition, complementary kit and application thereof
HK40007677A (en) Methods and compositions for treatment of epileptic disorders
WO2020188457A1 (en) Solutions for oral dosage
HK40065231A (zh) 延迟释放去铁酮片剂及其使用方法
HK1256349A1 (zh) 用於在危重监护治疗期间使用的镇静方法和肠胃外制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221104

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230908